Search
Close this search box.

Clinical Trial: ECOG-ACRIN EA5162

ECOG-ACRIN EA5162

Status: Open

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR